Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP7713 SAD/MAD Study in Healthy Volunteers
NCT03108755Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP7713 in underactive bladder (UAB) (6 arms), sponsored by Astellas Pharma. Primary endpoints: Safety as assessed by nature, frequency and severity of Adverse Events, Number of Participants with Vital Sign Abnormalities and/or Adverse Events and 7 more. Started May 2017; status: completed.
02
Drugs
ASP7713
03
Conditions
underactive bladder (UAB)
Beyond the preview
Go deeper on NCT03108755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03108755.